EUVIMEDEUVIMED entdecken
Open Access

Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV

Jiayu Xu iD, Michelle Chamblee iD, Fei Jiang iD, Mahesh Kc iD, Cheng Chih Hsu iD, Ilada Thongpan iD, Phylip Chen, Yuexiu Zhang, Chun-Ta Chiu, Mohamed M Shamseldin iD, Heba M Amer iD, Xueya Liang und 5 weitere

Science Advances · 2025

DOI: 10.1126/sciadv.adx7487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Jiayu Xu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Respiratory Syncytial Virus, Human, Genetic Vectors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Negative-sense RNA viruses have been widely used as viral vectors for vaccine delivery. However, little is known about coronaviruses as vectors for delivering vaccines. Here, we have developed safe SARS-CoV-2 Omicron JN.1–based live attenuated vaccine candidates by combining a mutation (D130A) in the viral nsp16 protein, deletion of the furin cleavage site (dFCS) in the spike protein, deletion of accessory proteins, and/or modification of the transcription regulatory sequences (mTRS). Subsequently, using rJN.1, rJN.1-D130A-dFCS, and rJN.1-mTRS-D130A-dFCS as the backbones, we generated three recombinant viruses expressing a nonfunctional, soluble, and stabilized prefusion F protein of human respiratory syncytial virus (RSVF). Among them, rJN.1-D130A-dFCS-RSVF virus was sufficiently attenuated and highly immunogenic, providing complete protection against challenge with both JN.1 and RSV in hamsters. However, rJN.1-mTRS-D130A-dFCS-RSVF was poorly immunogenic. Collectively, we demonstrate that attenuated SARS-CoV-2 is an effective viral vector for delivering RSV vaccine, warranting further development as a novel intranasal bivalent vaccine for SARS-CoV-2 and RSV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Respiratory Syncytial Virus, HumanGenetic VectorsCOVID-19 VaccinesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAnimalsHumansAdministration, IntranasalSpike Glycoprotein, CoronavirusVaccines, AttenuatedCricetinaeAntibodies, ViralVero Cells

Substanzen

Spike Glycoprotein, CoronavirusCOVID-19 VaccinesVaccines, AttenuatedRespiratory Syncytial Virus Vaccinesspike protein, SARS-CoV-2Antibodies, Viral

Autor:innen und Institutionen

  • Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
  • Center for Microbe and Immunity Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
  • Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA.
  • Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, USA.
  • Center for RNA Biology, The Ohio State University, Columbus, OH, USA.

ORCID-Profile: Jiayu Xu, Michelle Chamblee, Fei Jiang, Mahesh Kc, Cheng Chih Hsu, Ilada Thongpan, Mohamed M Shamseldin, Heba M Amer, Amal O Amer, Prosper N Boyaka, Estelle Cormet-Boyaka, Mark E Peeples, Jianrong Li

Förderung

  • NIAID NIH HHS

Zitieren

APA

Xu, J., Chamblee, M., Jiang, F., Kc, M., Hsu, C. C., Thongpan, I., Chen, P., Zhang, Y., Chiu, C. T., Shamseldin, M. M., Amer, H. M., Liang, X., Amer, A. O., Boyaka, P. N., Cormet-Boyaka, E., Peeples, M. E., & Li, J. (2025). Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV. Science Advances. https://doi.org/10.1126/sciadv.adx7487

Vancouver

Xu J, Chamblee M, Jiang F, Kc M, Hsu CC, Thongpan I, et al. Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV. Science Advances. 2025. doi:10.1126/sciadv.adx7487

BibTeX
@article{Xu2025,
  author = {Xu, Jiayu and Chamblee, Michelle and Jiang, Fei and Kc, Mahesh and Hsu, Cheng Chih and Thongpan, Ilada and Chen, Phylip and Zhang, Yuexiu and Chiu, Chun-Ta and Shamseldin, Mohamed M and Amer, Heba M and Liang, Xueya and Amer, Amal O and Boyaka, Prosper N and Cormet-Boyaka, Estelle and Peeples, Mark E and Li, Jianrong},
  title = {Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adx7487}
}
Kostenlos starten →